<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453206</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000538185</org_study_id>
    <secondary_id>CCCWFU-29506</secondary_id>
    <secondary_id>IRB00001366</secondary_id>
    <nct_id>NCT00453206</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases</brief_title>
  <official_title>Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients With Hematological Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor
      peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or
      abnormal cells. It also helps stop the patient's immune system from rejecting the donor's
      stem cells. When the healthy stem cells from a donor are infused into the patient they may
      help the patient's bone marrow make stem cells, red blood cells, white blood cells, and
      platelets. Sometimes the transplanted cells from a donor can make an immune response against
      the body's normal cells. Giving tacrolimus, methotrexate, mycophenolate mofetil, and
      antithymocyte globulin before and after transplant may stop this from happening. Once the
      donated stem cells begin working, the patient's immune system may see the remaining cancer or
      abnormal cells as not belonging in the patient's body and destroy them (graft-versus-tumor
      effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may
      boost this effect.

      PURPOSE: This phase II trial is studying how well donor stem cell transplant works in
      treating patients with hematologic cancer or other diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility (i.e., risk of treatment-related mortality during the first 6
           months after transplantation) of administering reduced-intensity allogeneic
           hematopoietic stem cell transplantation to patients with hematologic cancer or other
           diseases.

      Secondary

        -  Determine the response rate (partial and complete response), 6- and 12-month
           probabilities of response, and time to progression in patients treated with this
           regimen.

        -  Determine the risk of acute and chronic graft-versus-host disease in patients treated
           with this regimen.

        -  Determine other toxicities of this regimen in these patients.

        -  Determine the overall survival and disease-free survival of patients treated with this
           regimen.

        -  Determine the impact of iron status on overall and disease-free survival.

        -  Determine the influence of quality of life (at time of transplantation) on overall
           survival.

      OUTLINE:

        -  Preparative regimen: Patients receive fludarabine phosphate IV over 30 minutes on days
           -7 to -3. Patients also receive busulfan IV over 2 hours every 6 hours on days -4 and -3
           or melphalan IV over 2 hours on day -3.

        -  Graft-versus-host disease (GVHD) prophylaxis: Patients with matched related donors
           receive oral tacrolimus twice daily on days -1 to 90 followed by a taper until day 180.
           Patients also receive methotrexate IV on days 1, 3, and 6. Patients with matched
           unrelated and 9/10 matched related donors receive oral tacrolimus twice daily on days -1
           to 180 followed by a taper; methotrexate IV on days 1, 3, 6, and 11; and oral
           mycophenolate mofetil twice daily on days -2 to 60 followed by a taper. All patients
           also receive antithymocyte globulin IV over 4 to 6 hours once a day on days -4 to -1.

        -  Allogeneic stem cell transplantation: Patients undergo allogeneic peripheral blood stem
           cell transplantation or bone marrow transplantation on day 0. Patients receive
           filgrastim (G-CSF) beginning on day 7 and continuing until blood counts recover.

        -  Lymphocyte infusion: Patients with progressive or stable disease while off
           immunosuppression and no active GVHD may receive up to 3 donor lymphocyte infusions from
           the original donor at 8-week intervals beginning on day 180 or 210 .

      Quality of life is assessed at baseline.

      After completion of study therapy, patients are followed every 3 months for 2 years and then
      every 6 months for up to 3 years.

      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Mortality Within the First 6 Months After Transplantation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host Disease</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Status at the Time of Transplantation</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at the Time of Transplantation</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality at 100 Days After Transplantation</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed hematological disease, including any of the following:

               -  Chronic lymphocytic leukemia

                    -  Absolute lymphocytosis &gt; 5,000/µL

                    -  Morphologically mature lymphocytes with &lt; 55% prolymphocytes

                    -  Lymphocyte phenotype with expression of CD19 and CD5

                    -  Absence of CD23 expression allowed provided disease is morphologically
                       distinguished from mantle cell lymphoma

               -  Prolymphocytic leukemia

                    -  Absolute lymphocytosis &gt; 5,000/µL

                    -  Morphologically mature lymphocytes with &gt; 55% prolymphocytes

               -  Non-Hodgkin's or Hodgkin's lymphoma

                    -  Any WHO classification histologic subtype

                    -  Diagnosis by core biopsy allowed provided there is adequate tissue for
                       diagnosis and immunophenotyping

                    -  Diagnosis by bone marrow biopsy not acceptable for follicular lymphomas

               -  Multiple myeloma

                    -  Has received ≥ 1 prior treatment regimen

                    -  Has a partial response or greater by the Blade Criteria

                    -  Patients who achieved complete remission are eligible

               -  Acute myeloid leukemia

                    -  Documented control (i.e., &lt; 10% bone marrow blasts and no circulating
                       blasts)

               -  Myelodysplastic syndromes

                    -  Documented disease as defined by WHO or French-American-British Cooperative
                       group criteria

                    -  Chronic myelogenous leukemia

               -  Patients with atypical chronic myelogenous leukemia (i.e., absent Philadelphia
                  chromosome) are eligible

               -  Polycythemia vera

                    -  Documented disease as defined by WHO criteria (i.e., A1 + A2, and any other
                       category A, OR A1 + A2, and any 2 category B):

                         -  A1: Total red blood cell mass &gt; 25% above mean normal predicted value
                            OR hemoglobin &gt; 18.5 g/dL in males, 16.5 g/dL in females (hematocrit ≥
                            60% in males or ≥ 56% in females)

                         -  A2: No cause of secondary erythrocytosis (absence of familial
                            erythrocytosis, no elevation of epoetin alfa [EPO] due to hypoxia, high
                            oxygen affinity hemoglobin, truncated EPO receptor, or inappropriate
                            ectopic EPO production)

                         -  A3: Splenomegaly

                         -  A4: Clonal genetic abnormality other than the Philadelphia chromosome

                         -  A5: Endogenous erythroid colony formation in vitro

                         -  B: Platelet count &gt; 400,000/mm³, WBC &gt; 12,000/mm³, bone marrow biopsy
                            with prominent erythroid and megakaryocytic proliferation, and low
                            serum EPO

               -  Chronic idiopathic myelofibrosis

                    -  Documented disease as defined by WHO criteria

                    -  Must have a HLA-identical donor, a matched unrelated donor, or a HLA 9/10
                       related donor meeting the following criteria:

                    -  HLA-identical sibling (6/6)

                         -  Serologic typing for class I (A, B)

                         -  Molecular typing for class II (DRB1)

                    -  9/10 matched related donor

                         -  High-resolution molecular typing at HLA-A, B, C, DRB1, and DQB1

                         -  Only a single mismatch at one class I or II allele allowed

                    -  10/10 matched unrelated donor

                         -  Molecular identity at HLA-A, B, C, DRB1, and DQB1 by high-resolution
                            typing

                         -  Syngeneic donors are not eligible

          -  Creatinine clearance ≥ 40 mL/min

          -  Bilirubin ≤ 3 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  DLCO ≥ 40% with no symptomatic pulmonary disease

          -  LVEF ≥ 30% by cardiac MRI or echocardiogram with no symptomatic cardiac disease

          -  Fertile patients willing to use effective contraception

        Exclusion Criteria:

          -  Uncontrolled diabetes mellitus

          -  Active serious infection

          -  Known hypersensitivity to E. coli-derived products

          -  Known HIV positivity

          -  History of another malignancy*, meeting the following criteria:

               -  Non-skin malignancy or melanoma within the past 5 years

               -  Concomitant malignancy that has not been curatively treated

               -  NOTE: *However, cancer survivors who have undergone potentially curative therapy
                  for a prior malignancy at least 5 years before enrollment and are deemed at low
                  risk of &lt; 30% for recurrence by their treating physicians is considered

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hurd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <results_first_submitted>May 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage I childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage II childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage III childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Reduced Intensity Allogeneic Cell Transplantation</title>
          <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reduced Intensity Allogeneic Cell Transplantation</title>
          <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Mortality Within the First 6 Months After Transplantation</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Intensity Allogeneic Cell Transplantation</title>
            <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality Within the First 6 Months After Transplantation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft-versus-host Disease</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Status at the Time of Transplantation</title>
        <time_frame>baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life at the Time of Transplantation</title>
        <time_frame>baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality at 100 Days After Transplantation</title>
        <time_frame>100 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The only adverse events collected and analyzed for this study were grade 5 (death) related to transplant occurring within 6 months of transplant. No data was collected for less serious adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reduced Intensity Allogeneic Cell Transplantation</title>
          <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death of unknown cause</sub_title>
                <description>Cause of death could not be determined. Per study, this was considered related to transplant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Post transplant proliferative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>By the time the primary objective of this trial was completed, the treatment approach of the trial had become standard of care. Analysis was therefore limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Hurd, MD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-2843</phone>
      <email>dhurd@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

